Standard-of-care treatments for ER+ breast cancer (BC) commonly involve antagonising oestrogen receptor (ER) signalling using aromatase inhibitors or ERα antagonists1,2, ERα degraders (selective oestrogen receptor degraders (SERDs)) such as fulvestrant3 and more recently novel SERD molecules4–6. This evidence concerns the gene ESR1 and breast carcinoma.